Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9595556 | 0.87 | KCNA3 (0.47) | MEN1KMT2AKCNA3OPRM1 | |
| Trifluoroacetic Acid SCHEMBL5858602 | 0.86 | KCNA3 (0.59) | DPP4DPP7KCNA3OPRM1 | |
| Trifluoroacetic Acid SCHEMBL6703418 | 0.83 | KCNA3 (0.55) | DPP4DPP7KCNA3OPRM1 | |
| Trifluoroacetic Acid SCHEMBL5857174 | 0.81 | SLC6A2 (0.53) | DPP4DPP7SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL16114304 | 0.78 | PIK3CD (0.42) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL6079642 | 0.77 | KCNA3 (0.53) | CACNA1BMEN1KMT2AKCNA3 | |
| SCHEMBL6079635 | 0.77 | KCNA3 (0.53) | CACNA1BMEN1KMT2AKCNA3 | |
| SCHEMBL6080224 | 0.77 | KCNA3 (0.53) | CACNA1BMEN1KMT2AKCNA3 | |
| SCHEMBL24433074 | 0.76 | L3MBTL1 (0.51) | KCNA3 | |
| SCHEMBL4324168 | 0.76 | MEN1 (0.66) | MEN1KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | DPP4 590/4885DPP7 408/4885F2 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.